Guggenheim assumed coverage of Nuvalent with a Buy rating and $99 price target. In addition to having reported FY23 financials, management reiterated their recently announced “OnTarget 2026 operating plan” under which Nuvalent aims to execute on global registrational strategies in 2024, present pivotal data in 2025, and see their first regulatory approval in 2026, the analyst tells investors.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on NUVL:
- Nuvalent Highlights Pipeline Progress, Reiterates Key Anticipated Milestones and Reports Fourth Quarter and Full Year 2023 Financial Results
- Block upgraded, Rivian downgraded: Wall Street’s top analyst calls
- Baird starts Nuvalent at Outperform, sees ‘billion-dollar-plus opportunities’
- Nuvalent initiated with an Outperform at Baird
- Nuvalent initiates Phase 2 portion of ALKOVE-1 trial
